Form 4: Roivant Sciences Director Daniel Gold Receives Stock Options and Restricted Stock Units

Director Daniel Allen Gold received stock options and restricted stock units from Roivant Sciences Ltd. on September 10, 2024, according to a Form 4 filing.

Summary

• Daniel Allen Gold, a director at Roivant Sciences Ltd., received an annual award of 16,406 restricted stock units (RSUs) and 27,894 stock options on September 10, 2024.
• The RSUs and stock options were granted under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
• The RSUs will vest 100% on September 10, 2025, subject to continuous service.
• The stock options, with an exercise price of $12.19, will also vest and become exercisable 100% on September 10, 2025, and expire on September 9, 2034, subject to continuous service.
• Following the transaction, Gold directly owns 7,291,692 common shares and indirectly owns 2,656,245 common shares held by trusts and estate planning vehicles.
• Gold disclaims beneficial ownership of the shares held by trusts except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the company's future performance. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The RSUs and stock options are scheduled to vest on September 10, 2025, subject to the reporting person's continuous service through such date.

Industry Context

Granting stock options and restricted stock units to directors is a common practice to incentivize and retain key personnel in the biotechnology and pharmaceutical industries. This aligns with standard compensation practices among publicly traded companies.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation tools for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans for their directors.
• The vesting schedules and terms are generally in line with industry standards, promoting long-term commitment and alignment with shareholder interests.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders.
• The vesting schedule encourages the director's continued service, which can benefit employees and other stakeholders.

Key Dates